Calidi Biotherapeutics, Inc. (CLDI) Stock Forecast
CLDI analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 1 analysts
- Price target
- $120.00 average of analyst targets
- Upside to target
- +14,237.5% from the latest close
- Next earnings
- November 12, 2026
- 52-week range
- $0.84 – $26.56
CLDI analyst ratings
1 analystsNumber of analysts at each rating.
CLDI price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CLDI earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Next fiscal year (2026) | −$5.52 | −$5.52 | −$5.52 | −$7.44 | +25.8% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CLDI revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Next fiscal year (2026) | $0 | $0 | $0 | 0.0% | 1 |
CLDI EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CLDI EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Next fiscal year (2026) | −$3.96 | −$3.84 | −$3.84 | −$3.84 | −$5.52 | +39.4% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CLDI earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; CLDI beat in 3 of 9.
What analysts expect from CLDI
1 analysts cover Calidi Biotherapeutics; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $120.00, 14,237.5% above the latest close of $0.84. For 2026 the average estimate is −$5.52 per share. Calidi Biotherapeutics beat the EPS estimate in 3 of the last 9 quarters.
Related: CLDI income statement, CLDI key metrics, CLDI chart. See the CLDI stock overview for the latest quote and news.
CLDI forecast FAQ
What is Calidi Biotherapeutics's price target?
The average analyst price target for Calidi Biotherapeutics is $120.00, 14,237.5% above the latest close of $0.84.
Is Calidi Biotherapeutics a buy, hold or sell?
Of 1 analysts covering Calidi Biotherapeutics, 1 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
When does Calidi Biotherapeutics report earnings?
Calidi Biotherapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.
Does Calidi Biotherapeutics usually beat earnings estimates?
Calidi Biotherapeutics reported EPS at or above the analyst estimate in 3 of the last 9 quarters.